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Le fléau n’est pas à la mesure de l’homme, on se dit donc que le fléau 
est irréel, c’est un mauvais rêve qui va passer. Mais il ne passe pas 
toujours et, de mauvais rêve en mauvais rêve, ce sont les hommes qui 
passent, et les humanistes en premier lieu, parce qu’ils n’ont pas pris 
leurs précautions. 
 
 (A pestilence isn't a thing made to man's measure; therefore we tell ourselves that pestilence 
is a mere bogey of the mind, a bad dream that will pass away. But it doesn't always pass 
away, and from one bad dream to another, it is men who pass away, and the humanists first 
of all, because they haven’t taken their precautions.) 
 
Albert Camus, La Peste, 1947 
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Preface 
 
Paul Ehrlich described the concept of antimicrobial agents as “magic bullets” for 
killing microbes. This impression of antimicrobial agents as magic bullets was 
thoroughly reinforced when penicillin and other antibiotics came into clinical use in 
the 1940s. However, shortly after the introduction of these magic bullets in clinical 
practice, it was discovered that the bacteria were capable of developing resistance to 
the antimicrobials. The full magnitude of the resistance problem was not appreciated 
during the first decades of chemotherapy. However, bacteria became more resistant, 
new types of bacteria developed resistance, resistance genes spread among different 
bacteria, and resistant organisms spread to new geographical areas. Particularly 
serious resistance problems such as multidrug-resistant tuberculosis, methicillin-
resistant Staphylococcus aureus and extended-spectrum beta-lactamase (ESBL) 
producing Gram-negative bacteria emerged and spread to most parts of the world.  
Inappropriate use of antibiotics, use of broad-spectrum antibiotics, insufficient 
hygiene, immunosuppression and prolonged hospitalization may promote 
antimicrobial resistance. Use of antimicrobials of poor quality may contribute to 
emerging resistance and is a huge problem in countries with poor regulatory 
capacities. While antimicrobial resistance affects all countries, it has potential for 
doing more harm in developing countries since second-line antimicrobial drugs are 
often neither available nor affordable to those who need it. Diseases we have thought 
of as curable, such as pneumonia, bloodstream infections, typhoid fever and 
tuberculosis, may again become killers of people of all ages. If this scenario becomes 
real, developing countries may be where the harm will be felt first. 
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Summary 
Infectious diseases cause one in every six deaths worldwide. Antimicrobial drugs 
have helped dramatically in curing patients suffering from bacterial infections. 
However, emerging antimicrobial resistance in bacteria threatens to undermine the 
management of bacterial infections. Developing countries have greater burden of 
infectious diseases. A number of factors, which may promote antimicrobial resistance 
such as availability of antimicrobials without prescription, use of counterfeit or 
substandard antimicrobial drugs, suboptimal hygiene, immunosuppression due to 
malnutrition or HIV, may be more frequent in developing countries. At the same 
time, consequences of antimicrobial resistance may be felt harder in resource-poor 
settings, since second-line antimicrobial drugs for resistant bacteria may be 
unavailable or unaffordable. There are many unresolved questions regarding 
antimicrobial resistance in general, including regarding its impact on patient outcome. 
In Sub-Saharan, some studies on antimicrobial resistance have been done, but, by and 
large, the issue has received far too little attention.  
We set out to improve available antimicrobial susceptibility data in Tanzania. We 
implemented a free-of-charge computerized software (WHONET) for resistance 
surveillance in the University Teaching Hospital in Dar es Salaam. This exercise 
showed that resistance surveillance is feasible in the setting and provided useful data 
on antimicrobial resistance. The surveillance data indicated high rates of resistance to 
common antibiotics in Gram-negative bacteria. We performed a prospective, 
observational cohort study of bloodstream infections in 1828 admissions of children 
with fever or suspected serious infection at the hospital. We performed blood culture, 
malaria testing and HIV testing and collected clinical data from the study subjects. 
The study showed that a disturbingly high proportion of Gram-negative bacteria 
produced extended-spectrum beta-lactamases (ESBL), with prevalent genotypes 
being TEM-63, SHV-12 and CTX-M 15. The ESBL-producing bacteria had a high 
rate of resistance to almost all other available drugs, except for ciprofloxacin, and 
bloodstream infection caused by these multiresistant bacteria were associated with 
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extremely high case-fatality rates. The study showed that inappropriate treatment due 
to antimicrobial resistance, as well as malnutrition and HIV-infection, were risk 
factors for death in children admitted with bloodstream infections.  
We investigated an outbreak of pediatric / neonatal meningitis at Haydom Lutheran 
Hospital, finding that Salmonella serovar Enteritidis, resistant to ampicillin and 
susceptible to gentamicin, was the cause of the outbreak. Although the numbers were 
small, the case-fatality rate for meningitis caused by these organisms was 100% (5/5).  
Antimicrobial resistance varies greatly from one geographical area to another. Thus, 
data obtained at major hospitals in urban centers may not be representative for the 
whole country. We analyzed the antimicrobial susceptibilities of isolates of 
uropathogenic bacterial obtained from the urine of pregnant women in a rural area in 
Northern Tanzania. This study indicated that there is less antimicrobial resistance in 
E. coli isolates from this rural area than in isolates from the commercial capital, Dar 
es Salaam. In formulating guidelines for antimicrobial use this possible rural-urban 
difference should be taken into account.  
For some of the bacteria carrying resistance traits for multiple antimicrobials, there 
are actually no good alternative drugs available. Based on the findings of these 
studies, we recommend sober, rational use of antimicrobial drugs, restrictions on sale 
and use of antimicrobials, and attention to hygiene. 
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1. Background 
1.1 List of Abbreviations 
Bla  Beta-lactamase gene 
CLSI  Clinical and Laboratory Standards Institute (formerly NCCLS) 
DNA  Deoxyribonucleic acid 
ESBL  Extended-spectrum beta-lactamase 
HIV  Human immunodeficiency virus 
IMCI  Integrated management of childhood illness 
MecA  Methicillin resistance structural gene 
MIC  Minimum inhibitory concentration 
MRSA Methicillin resistant Staphylococcus aureus 
MUCHS Muhimbili University College of Health Sciences 
NCCLS National Committee for Clinical Laboratory Standards (Now CLSI) 
PBP  Penicillin-binding protein 
PCR  Polymerase chain reaction 
RNA  Ribonucleic acid 
UNICEF United Nations Children’s Fund 
Van A/B Vancomycin resistance genes A and B 
VRE  Vancomycin-resistant enterococci 
VRSA Vancomycin-resistant Staphylococcus aureus 
WHO  World Health Organization 
WHONET Antimicrobial resistance surveillance software from WHO  
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1.2 Definitions 
1.2.1 Antibiotics, antimicrobial agents and chemotherapy 
The word antibiotic is derived from the Greek words anti (against) and bios (life) and 
means, in principle, a substance, which kills any living organism. However, in 
medical practice it is taken to mean a substance, which is produced by a living 
organism and which kills or inhibits a bacterium. The classical example is penicillin 
which kills bacteria and which is produced naturally by the molds Penicillium 
chrysogenum and Penicillium notatum. The word antimicrobial comes from the 
Greek words anti (against), micros (small) and bios (life) and means a substance, 
which kills or inhibits microbes. It is mostly applied to substances working on 
bacteria (antibacterials), but can, in principal, also be applied to agents working on 
viruses (antivirals), fungi (antifungals) and parasites (antiparasitic agents). 
Antimicrobials include antibiotics produced by other organisms (e.g. penicillin, 
tetracycline, erythromycin), chemically modified antibiotics (e.g. doxycycline) as 
well as chemically produced substances (e.g. fluoroquinolones). The word cytostatic 
comes from the Greek words kytos (bag or cell) and statikos (causing to stop). 
Cytostatics are related to antibiotics in the sense that it is a substance, which kills 
living cells. However, in medical practice it is mostly applied to agents used to inhibit 
or kill cancer cells and some drugs used to inhibit immune processes involved in 
autoimmune diseases and in the rejection of transplanted organs. The word 
chemotherapy originates from Greek therapeia (curing, healing) and Arabic al-kimya 
(alchemy), which is believed to originate from either the Greek word khymos (sap, 
juice) or Khemia, an ancient name for Egypt. The word chemotherapy was first used 
by Paul Ehrlich to mean the treatment of infectious diseases with chemical 
substances.  
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1.2.2 Resistance, susceptibility and sensitivity 
Resistance comes from the Latin words re (against) and sistere (to withstand). In 
microbiology, the term antimicrobial resistance is used to describe the phenomenon 
when a microbe can grow and multiply despite the presence of an antimicrobial 
agent. Depending on the microbe involved we use the terms antibacterial, antiviral, 
antifungal or antiparasitic resistance. Both susceptibility and sensitivity are commonly 
taken to mean the opposite of resistance, however, they have slightly different 
meanings. The word susceptibility comes from the Latin words sub (up from under) 
and capere (to take) while the word sensitivity comes from the Latin word sentire (to 
feel). In microbiology susceptibility is understood as a continuous variable, i.e. it can 
be used not only to describe whether a microbe is susceptible or resistant to a an 
antimicrobial, but also to quantify the degree to which it is resistant or susceptible as 
expressed by for instance the MIC result of antimicrobial dilution test or the zone 
diameters recorded from disk diffusion tests. Sensitivity, on the other hand, is a 
categorical variable commonly used to describe the interpretation of the susceptibility 
test into main groups such as sensitive (S), intermediate sensitive (I) and resistant (R). 
1.2.3 Virulence and pathogenicity 
Virulence derives from the Latin word virus, and may be related to the Sanskrit word 
visha, both of which mean poison or venom. Pathogenicity derives from the Greek 
words pathos (suffering) and genesis (creation), and means the ability to produce 
diseases (suffering). In microbiology, both virulence and pathogenicity means the 
ability to cause disease, but pathogenicity generally refers to the binary aspect, i.e. 
can the microbe cause disease or not, while virulence is a measure of the degree to 
which a microbe causes disease as indicated by case fatality rates for instance. 
Virulence factors are particular molecules that are responsible for the disease-causing 
ability of the microbe, such as toxins, adherence factors, proteins that mediate 
invasion of host cells. Genes coding for virulence factors may be located in gene 
regions called pathogenicity islands, which can be transferred horizontally between 
bacteria.  
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1.2.4 Mortality, lethality and case-fatality rates 
Mortality is a measure of the proportion of the entire population that dies. Lethality is 
the proportion that dies due to a specific condition. In infectious diseases, the 
expression case-fatality rate is commonly used to describe the proportion that dies 
among those who contract a certain infectious disease. Thus, case-fatality rate is 
largely equivalent to lethality. Case-fatality rate is dependent not only of the 
proportion of observed deaths, but also on the rate of detection of the disease. This is 
particularly relevant in areas with poor coverage of health systems; for instance, in 
some areas of Central Africa, the described high case-fatality rates of hemorrhagic 
fevers is thought partly to be due to a low detection rate, i.e. a number of less severe 
cases go undetected by the local health system. The term ‘attributable mortality’ is an 
expression used in for instance case control studies, and refers to the excess mortality 
in those who have the case characteristic as compared to the controls.  
1.2.5 Bloodstream infections, bacteremia, septicemia and sepsis 
Bacterial infections of the bloodstream are recognized as important causes of 
morbidity and mortality [1]. However, there has been much debate regarding the 
understanding of the common terminology related to these infections. Traditionally, 
the term bacteremia has been used as a microbiological diagnosis meaning the 
presence of viable bacteria in circulating blood. The term septicemia is a combined 
clinical and microbiological diagnosis and is commonly used to mean cases that have 
both bacteremia and a clinical signs indicating severe infection. Commonly, 
septicemia includes also cases of candidaemia with clinical signs of severe infection. 
Sepsis is a clinical diagnosis, which means that there are both signs of clinical 
infection and signs of systemic response. An additional frequently used term is 
bloodstream infection. Bloodstream infection is largely equivalent to the meaning of 
septicemia described above, meaning clinical signs of infection and bacteremia or 
candidaemia. However, there has been some ambiguity regarding this term as well, 
and it is now commonplace to use the extended term ‘laboratory-confirmed 
bloodstream infection” to ensure a correct understanding, i.e. clinical infection plus a 
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verified bacteremia or candidaemia. In the articles presented in this thesis we have 
used both the term septicemia (paper 3 & 4) and laboratory-confirmed bloodstream 
infection (paper 2, thesis) as interchangeable terms, meaning clinical signs of 
infection and verified bacteremia or candidaemia. The current understanding of the 
terminology is based on the description by Bone et al [2] with modifications 
applicable for infants and children as described by Jafari and McCracken [3] as 
summarized in Table 1 (the table was not presented in the articles). 
Table 1.  Definitions 
Bacteremia Presence of viable bacteria in the circulating blood confirmed by blood culture 
Sepsis Clinical suspicion of infection accompanied by evidence of a systemic response 
manifested by at least two of the following conditions  
a) High (>38'C) or low (<36'C) body temperature,  
b) Elevated heart rate (adults >90, children >150 and infants >160 
beats/minute) 
c) High respiratory rate (adults >20/min, children >50/min and infants 
>60/min) 
d) Elevated (>12,000/mm3) or low (<4,000/mm3) white blood cell count 
Sepsis syndrome/ 
severe sepsis 
Sepsis plus evidence of altered organ perfusion manifested by at least one of the 
following acute changes: 
a) Acute changes in mental status (reduction by 3 in Glasgow coma scale or 
Simpson and Reilly or Jacobi modification for children) 
b) Oliguria 
c) Elevated blood lactate 
d) Hypoxemia 
Septic shock Severe sepsis with hypotension (systolic blood pressure (mmHg: Adults <90 or 40 
below baseline, children <75 and infants <65, or <5th percentile for age), which is 
responsive to therapy with i.v. fluids. 
Refractory septic 
shock 
Septic shock with hypotension, which lasts for more than one hour and is not 
responsive to i.v. fluid and pharmacological therapy, and requires vasopressor 
therapy 
Multiorgan failure Any combination of disseminated intravascular coagulation (DIC), respiratory 
distress syndrome, acute renal failure, hepatobiliary dysfunction and central 
nervous system (CNS) dysfunction 
 
1.2.6 Asymptomatic bacteriuria and urinary tract infection 
Asymptomatic bacteriuria is commonly defined as the finding of >100,000 bacteria 
per ml urine in a single midstream urine in a person with no symptoms of urinary 
tract infection. Urinary tract infection is the finding of >100,000 bacteria per ml urine 
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in a person with symptoms suggestive of urinary tract infection such as dysuria and 
frequent micturation. 
1.3 Bacterial infections 
Infectious diseases are responsible for an estimated 17.8% of all deaths world-wide, 
amounting to almost 10 million deaths per year [4]. While the majority of incidents of 
cardiovascular and neoplastic diseases affect the older part of populations and are 
important causes of death in developed countries, infectious diseases have an 
important impact on children and young adults, particularly in countries with scarce 
economical resources. In Africa, one in every six children dies before reaching the 
age of five years [5]. Malnutrition and infectious diseases are the main killers. 
However, it is notoriously difficult to assess which diseases contribute most to the 
suffering and death in the world because proper diagnostic tools are not available in 
large areas of the world and because many patients suffer from more than one 
condition at the time. Particularly, many children dying with infectious diseases are 
also suffering from severe malnutrition and it may be difficult to say which is 
contributing most to the suffering and death of the patients. Similarly, people dying 
with HIV infection almost invariably have one or more other conditions such as 
tuberculosis, other bacterial and parasitic infections and cancers. Thus, poverty, 
malnutrition and immunosuppression by HIV or other causes, all contribute to the 
complex picture of infectious diseases in the developing world. The World Health 
Organization (WHO) rank the major causes of mortality in children younger than five 
years in Africa as neonatal causes (26%, among which the entity “sepsis or 
pneumonia” contributes a quarter), pneumonia (21%), malaria (18%) diarrhea (16%) 
and HIV-infection (6%) [6]. 
1.3.1 Bloodstream infections 
Bloodstream infection is an important contributor to morbidity and associated case-
fatality rates exceed 25% [7, 8]. However, as bloodstream infection often occurs as 
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part of localized infections with defined foci, the significance of bloodstream 
infection as a death cause is often not reflected in published figures. Based on clinical 
examination alone, bacterial/fungal bloodstream infection and malaria are practically 
impossible to differentiate [9]. The WHO’s IMCI guidelines have been reported to 
fail to identify up to half of the cases of bacterial bloodstream infections [10]. A 
recent study from Kenya [8] showed that bloodstream infection is the cause of death 
in approximately one quarter of the children who died in the hospital, outnumbering 
even malaria deaths. Bloodstream infection is associated with both malnutrition and 
HIV [8, 11]. The causative agents in bloodstream infections differ among various 
settings, and nontyphoid salmonellae are the predominant cause of bloodstream 
infections in children in Africa [12]. 
1.3.2 Meningitis 
Bacterial meningitis is a serious infection associated with high case-fatality rates. 
Pneumococci, meningococci are common causes of meningitis. Haemophilus 
influenzae is decreasing dramatically as a cause of meningitis after the 
implementation of vaccine against H. influenzae type B. At the extremes of age, in 
neonates and old people, E. coli, other Gram-negatives and Listeria monocytogenes 
are important causes of meningitis, while Group B streptococci are particularly 
important in neonates. Nontyphoid salmonellae are an uncommon cause of meningitis 
in economically developed countries [13], but more common in tropical countries, 
particularly in children younger than six months, and often associated with higher 
case-fatality rates than meningitis caused by other bacteria [12, 14-16].  
1.3.3 Asymptomatic bacteriuria and urinary tract infection in 
pregnant women 
In non-pregnant women, asymptomatic bacteriuria is considered a harmless condition 
and is usually not treated with antimicrobials. However, asymptomatic bacteriuria 
affects five to ten percent of all pregnant women [17-22], among whom untreated 
asymptomatic bacteriuria may progress to pyelonephritis in as much as 20-30 percent 
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of cases. The reason for the much more serious implications of asymptomatic 
bacteriuria in pregnancy is thought to be mechanical obstruction of urinary flow from 
the enlarged uterus combined with hormonally (progesterone) mediated dilatation of 
the ureteres and renal pelvis, which favors ascending infection to the kidney [23]. 
Approximately 30-40% of all preterm deliveries are estimated to be caused by 
various infections, including urinary tract infections [24]. Pyelonephritis in pregnancy 
is associated with increased morbidity and mortality for mother and child, and if left 
untreated causes preterm birth in 20-50%. Studies have shown an association between 
asymptomatic bacteriuria in pregnancy and preterm delivery/low birth weight 
(<2500g) [19], but it has not been established whether asymptomatic bacteriuria is a 
separate risk factor or merely an indicator for low socioeconomic status, which is 
known to be associated with low birth weight [20].  
1.3.4 Clinical assessment of sick children and IMCI 
During the 1990s, the World Health Organization (WHO), UNICEF and other 
agencies developed the strategy known as Integrated Management of Childhood 
Illness (IMCI) in an attempt to integrate the many proven strategies for prevention 
and treatment of disease in children, and thereby increasing the number of lives 
saved. The diagnostic and treatment practices at MUCHS are generally rooted in the 
IMCI guidelines. In the study of bloodstream-infections in children (paper 2 and 3) 
we used the IMCI guidelines as a base for development of the questionnaire, 
classification of the patients and analysis of the data.  It is beyond the scope of this 
thesis to review the whole IMCI strategy, but I will mention some of the most 
important decision tools used for classifying patients.  
The following four signs were considered general danger signs, and patients were 
classified according to the number of danger signs present: 1) convulsions (may 
indicate cerebral malaria, meningitis or other serious illness), 2) lowered level of 
consciousness, 3) inability to drink/eat and 4) vomiting. The following three signs 
were considered suggestive of pneumonia: 1) high respiratory rate, 2) lower chest 
wall indrawing and 3) stridor. The normal respiratory rate varies by age, and thus we 
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consider different cut-off points for fast respiration as follows: 60 pr minute for 
young infant up to 2 months age, 50 pr minute for children aged 2 -12 months and 40 
pr minute for children from 12 months to 5 years. We used the cut-off of 40 pr minute 
also for children aged 6 and 7 years, although the IMCI framework does not cover 
this age group.  
1.4 Resistance to antimicrobial agents 
1.4.1 Historical background  
Penicillin was first discovered in 1928 [25], but it was not until the 14th of March 
1942 that the first patient was successfully cured from infection with penicillin by 
Drs Bumstead and Hess. The drug went on to have a significant impact on saving 
lives during World War 2. The success with penicillin, anti-tuberculosis drugs and 
other antimicrobials had dramatic effect on the treatment of infectious diseases and 
led to a great deal of optimism. In 1969, the US Surgeon General summarized this 
enthusiasm with the following historical words to the Congress "The time has come 
to close the book on infectious disease." While many praised this vision, the realities 
of infectious diseases were to take an unexpected and completely different course in 
the following period.  
Even before penicillin was used clinically, Abraham and colleagues had discovered 
an enzyme capable of destroying penicillin [26, 27]. By 1950, half of the S. aureus 
isolates were resistant to penicillin [28]. Penicillin-resistance first became prevalent 
among hospital-acquired staphylococci [29], but by the late 1960s also in community-
acquired infections [30]. However, the implications of antimicrobial resistance were 
seriously underestimated and there was widespread confidence that science would 
find new solutions to this problem. Methicillin, introduced in 1959, offered a solution 
for treating penicillin-resistant staphylococci, however, already in 1961 Jevons 
described the first methicillin-resistant S. aureus (MRSA) [31]. Vancomycin was 
approved for clinical use in 1958 and was suitable to treat MRSA, and later on other 
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problem-organisms such as enterococci, various streptococci and Clostridium difficile 
[32]. By 1986, vancomycin-resistance started to emerge in enterococci in Europe 
[33]. The infectious disease experts feared that the much more virulent S. aureus 
would acquire resistance to vancomycin too. In 1997, vancomycin-intermediate 
resistant S. aureus (VISA) was discovered in Japan [34], and as recently as in 2002, 
the first clinical isolate of fully vancomycin-resistant S. aureus (VRSA) was isolated 
from a patient in Michigan, USA [35].  
Similar developments of emerging resistance went on in other organisms, including 
Gram-negative bacteria. In 1948, Guiseppe Brotzu discovered that a substance 
produced by Cephaloporium acremonium effectively killed Salmonella typhii, laying 
the foundation for a whole new group of beta-lactam antibiotics, the cephalosporins. 
Starting with the use of cefalotin in 1964, the first-generation cephalosporins were 
succeeded by second-generation cephalosporins such as cefuroxime, and later on the 
third-generation oximino-cephalosporins, such as cefotaxime and ceftriaxone, which 
became fundamental in the treatment of Gram-negative bacteria, and ceftazidime, 
which had additional anti-pseudomonas effect. Ampicillin, the first penicillin with a 
broad-spectrum and activity against Gram-negative bacteria, was introduced in the 
early 1960s. Shortly after, Datta and colleagues in Greece described in a strain of E. 
coli a plasmid-mediated ampicillin-hydrolyzing beta-lactamases, which was named 
TEM-1 after the patient, whose name was Temoniera [36]. Another beta-lactamase, 
SHV-1, which is chromosomal in many strains of Klebsiella spp., spread via plasmids 
to E. coli, and other Enterobacteriaceae. The use of ampicillin selected for the spread 
of TEM-1 and other beta-lactamases. In 1985, Kliebe and colleagues discovered, 
SHV-2, the first extended-spectrum beta-lactamase (ESBL) capable of hydrolyzing 
third-generation cephalosporins in an isolate of Klebsiella ozaenae [37]. In the 
coming years, mutations have lead to the emergence of a large number of ESBL 
enzymes [38], currently counting over 100 in the TEM-family and over 50 in the 
SHV-family. Another type of ESBL, the CTX-M group, has probably evolved from 
chromosomal beta-lactamases in Kluyvera spp., and is particularly effective in 
hydrolyzing cefotaxime. The CTX-M group of ESBL now counts more than 40 
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variants, divided into 5 sub-classes, and is spreading fast, including in community-
acquired isolates. Other beta-lactamases which are counted among the ESBLs are 
VEB, PER, GES and OXA.  
Resistance to oximino-cephalosporins also emerged in Enterobacter spp. and other 
Gram-negatives by mutations in inducible chromosomal class C (AmpC) beta-
lactamases, resulting in “derepressed” mutants, which produce these beta-lactamases 
in abundance. AmpC beta-lactamases have also migrated from chromosomal 
locations to plasmids and are spreading into E. coli and Klebsiella spp.  
As the medical community started to realize the magnitude of the resistance problem, 
another catastrophe struck with the dawn of the HIV epidemic in the early 1980s. 
According to UNAIDS, there are currently almost 40 million people infected with 
HIV and 3 million people dying from this disease every year [39]. As HIV infection 
progresses, the individual becomes susceptible to bacterial and other infections which 
needs treatment with antimicrobials. Persons infected with HIV also experience fever 
episodes for other reasons than bacterial infections, and may thus consume more 
antimicrobials than others. Use of antibacterial agents, particularly broad-spectrum 
agents such as cephalosporins, is a known risk factor for infection with resistant 
bacteria. There is evidence of an association between HIV infection and bacterial 
resistance, and this has been linked to co-trimoxazole prophylaxis against 
Pneumocystis jirovecii pneumonia [40-42]. Thus, the HIV epidemic may contribute 
substantially to the resistance problem. 
The optimism of the “golden age” of antibiotics, has given way to a reserved feeling, 
as bacteria have generated resistance against virtually any antimicrobial agent that 
humans have developed. While the pharmaceutical industry has largely been passive 
in developing new antimicrobials the last few decades, the emergence of VRSA [35, 
43], plasmid-mediated AmpC and carbapenemases [44], seem to herald that we may 
be entering what Cohen called the post-antibiotic area [45]. 
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1.4.2 Consequences of antimicrobial resistance 
Intuitively, antimicrobial resistance leads to ineffective chemotherapy, which 
subsequently leads to treatment failure, increased morbidity, increased cost and, 
ultimately, increased risk of death [45-47]. According to WHO, infections with 
resistant organisms are more often fatal and lead to prolonged illness [48]. Due to the 
prolonged illness, there is greater risk of spread of the infection to other people. Costs 
are increased, not only because of the use of more expensive antimicrobials, but also 
because of longer duration of care and hospitalization. Prompt treatment with 
appropriate antibiotics is essential to prevent serious complications and death, 
particularly in serious infections such as bloodstream infections. While this reasoning 
seems obvious, there is not extensive scientific proof of this association, and studies 
assessing the association between resistance and adverse outcome are challenging for 
a number of reasons [49]. Firstly, confounding factors may influence the outcome. In 
particular, various underlying conditions are important to consider. It can sometimes 
be difficult to tell whether the adverse outcome is the result of an underlying disease 
or a consequence of antimicrobial resistance in the bacteria causing the infection. 
Furthermore, the design of the study, particularly, the choice of reference group, has 
great impact on the conclusions. Whether comparing patients with infections caused 
by resistant organisms to patients with infections with similar, but non-resistant 
bacteria, or comparing to those without infection, makes a big difference. The first 
design would evaluate the effect of having a resistant bug as compared to having a 
susceptible bug, while the last design would measure the combined effect of having 
an infection and having an infection with resistant bacteria. Thus, the choice of 
reference group becomes increasingly important the more virulent the bacteria in 
question are [50]. Many published studies are retrospective, while more reliable 
information would be obtained from prospective studies. Furthermore, the size of 
studies also limits the ability to detect associations, if the number of observations is 
too small, a biological difference might not be detected. Thus, meta-analysis of the 
data obtained from several studies is sometimes used to increase the data set and thus 
increase the chance of detecting differences. The challenge with meta-analyses is that 
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the studies on which it is based may not be designed in the same way so that they 
may not be directly comparable.  Finally, the type of study outcome will influence the 
chance of actually measuring a difference. In economically developed countries, cost 
and morbidity are more sensitive measures of resistance than its impact on mortality 
[49]. In many low-income countries, the surge in antimicrobial resistance is seen as 
potentially disastrous because of the lack of resources for purchasing expensive 
second-line drugs [51-53]. However, while this notion appears plausible, again, there 
is lack of evidence of an association between antimicrobial resistance and adverse 
outcome in developing countries. 
Impact antimicrobial resistance on morbidity 
Frequently, duration of hospital stay is used as a proxy for morbidity.  It is intuitive 
that inappropriate chemotherapy would lead to more suffering for the patient. Several 
studies have documented an association between increased duration of hospital stay 
and infections with resistant bacteria [49]. The duration of hospital stay significantly 
(p<0.001) increases if S. aureus surgical site infections are caused by methicillin-
resistant strains [54]. Likewise, the patients with infections caused by penicillin-
resistant pneumococci stay longer in hospital than those with penicillin-susceptible 
pneumococci [55]. Infection with ESBL-producing E. coli and Klebsiella spp. is also 
associated with increased duration of hospital stay [56]. 
Cost implications of antimicrobial resistance 
The cost of treating patients with infections caused by resistant bacteria increases due 
to the higher cost of second-line drugs and the longer duration of hospital stay. 
Significant association between infection with resistant causative microbe and higher 
cost has been shown for penicillin-resistant pneumococci [55], methicillin-resistant S. 
aureus bacteremia [57] and ESBL-producing E. coli and Klebsiella spp. [56]. 
Impact antimicrobial resistance on mortality 
Many highly resistant bacteria, such as enterococci, have relatively little virulence 
and foremost cause disease in hospitalized patients with serious underlying diseases 
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and/or immunosuppression. In these cases, it may be difficult to determine whether 
the adverse outcome is related to the resistance or to the underlying conditions. Still, 
both prospective [58, 59] and retrospective studies [60-63] have shown an increased 
risk of death from enterococcal infections if it is caused by VRE, although two of 
these studies used patients without enterococcal infections as controls [60, 63].   
Meta-analyses of available studies on bacteremia caused by S. aureus found that 
patients with MRSA had increased risk of fatal outcome compared to those with 
methicillin-sensitive S. aureus [64, 65]. A prospective study of hemodialysis patients 
with S. aureus bacteremia showed increased risk of death in patients with MRSA 
infection compared to those with MSSA. Similarly, surgical site infections with 
MRSA have been associated with increased risk of fatal outcome in prospective 
studies [54].  
In infections caused by pneumococci, there has not been established any significant 
association between penicillin resistance and increased case-fatality rates [66-68]. 
Possible explanations for this observation could be that penicillin-resistant 
pneumococci may be less virulent, that patients acquire pneumococcal infections in 
the community and thus may have less underlying disease, or that empirical use of 
appropriate antimicrobial agents, such as vancomycin, is high in areas where 
penicillin-resistant pneumococci are prevalent. 
A number of studies have assessed the effect resistance on outcome of infections 
caused by Gram-negative bacteria. Both for Pseudomonas aeruginosa [69] and for 
Enterobacter  spp., the emergence of resistance in the causative isolate  during 
treatment has been linked to increased case-fatality rates. A recent review by 
Cosgrove and colleagues in a leading journal [49] reported no studies showing 
significantly increase in case-fatality rates associated with infections with ESBL-
producing Gram-negative bacteria, referring to a retrospective matched cohort study 
by Lautenbach and colleagues [56]. A previous retrospective study from South Korea 
does however report increased case-fatality rates in pediatric cases of bacteremia 
caused by ESBL-producing E. coli and Klebsiella spp. compared to those caused by 
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non-ESBL-producing isolates [70], although the reported figure was obtained by 
univariate analysis (patients dying from underlying diseases had been removed from 
the analysis). A microbiologic case-control study from Chicago [71] revealed that 
patients with bacteremia caused by ceftazidime-resistant E. coli and  Klebsiella spp. 
were more likely to survive (p=0.02) if they received appropriate treatment within 3 
days of start of the bacteremic episode. 
1.4.3 Resistance mechanisms 
The mechanisms for antimicrobial resistance in bacteria can be divided into three 
broad categories 1) enzymatic inactivation of the antimicrobial agent, 2) substitutions, 
amplifications or modifications of the drug target reducing the affinity of the drug to 
the target or 3) Reduced access of the antimicrobial agents to the target by means of 
permeability barriers or efflux pumps [72, 73]. 
Enzymativ inactivation of the antimicrobial agent 
The typical example of enzymes, which inactivate the antimicrobial agent, is the beta-
lactamases. The beta-lactamases are enzymes, which destroy beta-lactams. They may 
be chromosomal or plasmid-mediated and are involved in resistance in S. aureus, 
Gram-negative rods, gonococci and Haemophilus influenzae. They differ in 
antimicrobial spectrum from the simple penicillinases capable of hydrolyzing benzyl-
penicillin, to more broad-spectrum beta-lactamases, such as TEM-1, which 
hydrolyzes ampicillin, to extended-spectrum-beta-lactamases, which hydrolyze 
oximino-cephalosporins, AmpC beta-lactamases, which are also inhibitor-resistant, 
and carbapenemases which neutralizes even carbapenems.  
Furthermore, enzymatic modification of a variety of antimicrobials can occur by 
means of cytoplasmic modifying enzymes. Enzymatic degradation by 
aminoglycoside modifying enzymes (aminoglycoside phosphotransferases APH, 
acetyltransferases AAC and nucleotidyltransferases ANT) is an important mechanism 
for resistance to aminoglycosides in Gram-negative rods and enterococci. Enzymatic 
modification or inactivation can cause resistance to chloramphenicol 
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(chloramphenicol acetyl transferase), macrolide resistance in Enterobacteriaceae and 
staphylococci (EreA, EreB) and resistance to streptogramin A (acetyltransferase) and 
streptogramin b (hydrolyzing enzymes, vgb, vgbB). The tetX gene encodes a 
tetracycline-inactivating enzyme, but its clinical importance is not well known [73]. 
Altered target of the antimicrobial agent 
Beta-lactams exert their antimicrobial action by inhibiting the transpeptidase and 
carboxypetidase activities of the cell-wall synthesizing enzymes, the so-called 
penicillin binding proteins (PBP). The mechanism for resistance to methicillin in S. 
aureus is alteration of the PBP. The mecA gene encodes an altered PBP, called PBP2a 
or PBP2’, which has reduced affinity for beta-lactams, thus methicillin-like drugs 
such as cloxacillin will not be able to interfere with cell-wall synthesis. Penicillin-
resistance in pneumococci is also caused by altered PBP. Pneumococci commonly 
have 6 PBPs, PBP1a, PBP1b, PBP2a, PBP2b, PBP2x, and PBP3. Resistance is the 
result of altered pbp1a, pbp2b, and pbp2x low-affinity, which are encoded by mosaic 
genes believed to contain gene material acquired from other species such as 
Streptococcus mitis [73]. The glycopeptides, vancomycin and teicoplanin, exert their 
action by binding to the D-alanyl–D-alanine side chains of peptidoglycan, thus 
preventing the cross-linking of the pedtidoglycan chain and thereby disrupting cell 
wall synthesis. Resistance to vancomycin and teicoplanin is the result of the 
production of a different ligase, VanA, encoded by the vanA gene, which produces 
peptidoglycan side chains with less affinity for glycopetide antimicrobials. The 
vanB1-3 genes only confer resistance to vancomycin, not teicoplanin. While 
vancomycin-resistant enterococci are important pathogens in nosocomial infections 
and immunocompromised hosts, unfortunately, vancomycin-resistance has recently 
become a reality also in the much more virulent S. aureus (VRSA) [35, 43].  
Protein synthesis in the ribosomes is the main target of a number of antimicrobials, 
including aminoglycosides (gentamicin, tobramicin, streptomycin), tetracyclines and 
the MLS group of antimicrobials macrolides, lincosamins and streptogramins, and 
alterations of ribosomal targets can result in resistance to these drugs. MLS 
Bjørn Blomberg 29 
antimicrobials have a wide selection of resistance mechanisms. In Gram-positive 
bacteria, alteration in 23S rRNA mediated by erm genes leads to resistance to 
macrolides, lincosamines and streptogramin B, but does not affect streptogramin A 
[73]. While aminoglycoside modifying enzymes are quantitatively more important, 
altered rRNA can also lead to resistance to aminoglycosides. Altered ribosomal target 
(TetM) causes tetracycline resistance in gonococci and S. aureus. 
Quinolones exert their antimicrobial action by inhibiting the DNA gyrase, which is 
pivotal in the coiling of DNA. The primary mechanism responsible for resistance to 
fluoroquinolones in Gram-negative rods is alteration of the DNA gyrase, particularly 
the GyrA subunit encoded by the gyrA gene. In Gram-positive organisms, alteration 
of the topoisomerase IV confers resistance.  
The folate inhibitors, trimethoprim and the sulfonamides, exert their antimicrobial 
action by inhibiting folic acid synthesis in the target organism. Resistance to folate 
antagonists is caused by altered target enzymes, DHFR for trimethoprim and DHPS 
for sulfonamides. 
Impaired access of the antimicrobial agent  
Bacteria can reduce the access of antimicrobials by two principle ways, reduced 
permeability for the drug or by efflux pumps that remove the drugs from the cell. 
Reduced permeability makes Gram-negative bacteria inherently resistant to 
macrolides, lincosamines and streptogramines, and causes resistance to beta-lactam 
antimicrobials and aminoglycosides in Pseudomonas aeruginosa and E. cloacae [73].  
Macrolide efflux pumps cause resistance to macrolides in staphylococci, and 
tetracycline efflux pumps cause resistance to tetracyclines in both Gram-negatives 
and Gram-positives (TetA-E and TetG-H). Efflux pumps (NorA) also cause 
resistance to fluoroquinolones in Gram-negative rods and S. Aureus. 
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1.4.4 How does resistance emerge and spread 
Selection pressure and risk factors 
The mold growing and inhibiting bacteria on Fleming’s agar plates [25] probably 
developed the bactericidal substance, penicillin, as a means to survive in a natural 
environment in competition with numerous other organisms. In a similar manner, 
bacteria develop antimicrobial resistance mechanisms as a defense against any, for 
them, toxic substance, which nature or humans throw at them. Thus, antimicrobial 
resistance is a natural phenomenon, which helps microbes survive in an environment 
with toxic substances. In an environment free of the particular toxic substance or 
antimicrobial agent, the presence of antimicrobial resistance mechanisms may incur a 
cost for the bacterium. However, in an environment where antimicrobials are present, 
such as hospital settings, bacteria harboring resistance mechanisms get an advantage 
in surviving by Darwinian selection [74]. Consequently, any use of antimicrobial 
drugs, whether appropriate or not, has the potential to lead to the selection of resistant 
bacteria [75, 76]. In Europe, it is striking that both outpatient antimicrobial 
consumption and antimicrobial resistance rates are higher in Southern European 
countries than in Northern Europe [77].  
While even appropriate antimicrobial use may select resistant bacteria, this problem 
is bound to be greater with exaggerated and irrational use of drugs. Using narrow-
spectrum antimicrobials in a sufficient dose, for the correct duration, kills off the 
intended bacteria, while leaving the least possible effect on the natural flora of the 
host. Conversely, using unnecessarily broad-spectrum antimicrobials leads to a higher 
degree of “collateral damage” in terms of unwanted ecological effects, selection of 
resistant bacteria and colonization or overt infection with resistant bacteria [78]. 
Cephalosporin and fluoroquinolones have been embraced by clinicians for their 
combination of bactericidal properties towards a broad spectrum of relevant clinical 
pathogens and their relatively infrequent side effects. However, there is increasing 
evidence to link cephalosporin use to infection with ESBL–producing Klebsiella 
pneumoniae, vancomycin-resistant enterococci and “antibiotic-associated diarrhea” 
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caused by Clostridium difficile. Similarly, use of fluoroquinolones is associated with 
MRSA infections and increasing rates of resistance to fluoroquinolones in Gram-
negative bacilli, including Pseudomonas aeruginosa.  
Inappropriate use of antimicrobial therapy may further increase the risk of selecting 
resistant bacteria, since sub-therapeutic drug levels may only suppress bacteria, but 
not eradicate them, thus increasing the number of bacteria that are exposed to the 
drug and the time of exposure, and allowing for the survival of partially treated 
microbes. Inappropriate use of antimicrobials is common and may be propelled by 
erroneous prescription and availability of antimicrobials over-the-counter without 
prescription [79, 80]. In developing countries, the use of poor-quality and counterfeit 
pharmaceuticals is an extremely serious problem, which appears to be disturbingly 
widespread [81-85]. If available drugs are of poor-quality, even the best attempt at 
rational treatment will become de facto inappropriate.  
Besides the use of antimicrobials, other factors have been identified as risk factors for 
acquiring infections with resistant bacteria. Risk factors for hospital-acquired 
infections with ESBL-producing bacteria are admission to intensive care units, 
receipt of parenteral nutrition, use of indwelling catheters, renal failure and burns 
[86]. Risk factors for acquiring infections with ESBL-producers outside hospitals are 
antimicrobial treatment during the last 3 months, particularly with cephalosporins, 
age over 60 years, underlying diabetes and a history of recent hospitalization [87]. 
Finally, the HIV epidemic may also contribute to the current worldwide surge in 
antimicrobial drug resistance [40-42].  
Acquisition and spread of resistance traits 
Some resistance traits are inherent to particular bacteria such as ampicillin-resistance 
in Klebsiella pneumoniae, cephalosporin-resistance in enterococci and erythromycin-
resistance in many Gram-negative bacteria. Other resistant traits are acquired. 
Bacteria can acquire resistance traits by three principally different ways: 1) 
accumulation of mutations in the bacterial chromosome, 2) acquisition of a new gene 
and 3) intrageneic recombination of genes to form mosaic genes which encode 
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resistance traits [88]. Examples of mutations leading to antimicrobial resistance are 
the mutations in gyrA, gyrB, parC, parE genes leading to fluoroquinolone resistance 
and the mutation in the rpoB gene in M. Tuberculosis leading to rifampicin 
resistance. Acquisition of new genes encoding for resistance traits can occur by 
different mechanisms such as plasmid transfer and conjugation, which occurs in both 
Gram-positive and Gram-negative bacteria, and transformation and transduction in 
Gram-positive bacteria. Intrageneic recombination of genes is the cause of emergence 
of penicillin-resistance in pneumococci [88].  
Resistance traits can spread by proliferation of the bacteria harboring these traits, so-
called vertical transfer, which means that resistant bacteria multiply and get offspring 
with similar resistance traits. Poor hygiene allows resistant bacteria to spread more 
easily. In hospitals where there is a high consumption of antimicrobials, resistant 
bacteria get a competitive advantage over susceptible ones.  In addition, resistance 
genes may spread horizontally among bacteria, e.g. via plasmids. There is evidence 
that coliform bacteria can exchange plasmids with resistance genes in the gut [89, 
90]. 
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2. Rationale for the study 
Bacterial infections are a major cause of morbidity and mortality, particularly in low-
income countries [4-6]. The global emergence of antimicrobial resistance undermines 
the management of infectious diseases [45, 46, 49]. Availability of antimicrobials 
without prescription, use of poor-quality antimicrobials and other factors, which 
promote the emergence of antimicrobial resistance, may be more frequent in 
developing countries [81-85]. At the same time, the consequences of antimicrobial 
resistance may be felt harder in a setting of scarce economical resources, because 
alternative antimicrobial drugs tend to be unavailable or unaffordable [51-53, 91]. 
The HIV epidemic may influence both the spectrum of bacteria causing infections 
[92, 93] and their antimicrobial resistance patterns [41, 94, 95]. Despite its obvious 
importance, there is little published information on antimicrobial resistance in the 
developing world. Available data from Tanzania [96-98] and neighboring countries 
[99-104] suggested there was significant rates of antimicrobial resistance particularly 
in Gram-negative bacteria. Since antimicrobial resistance varies greatly among 
geographical locations it is essential to base empiric therapy of serious infections 
such as bloodstream infections on sound knowledge of the prevalence and 
antimicrobial resistance patterns of local bacterial isolates [105]. The rationale for the 
study was to gain more insight into the epidemiology of certain bacterial infections 
and their resistance patterns in selected areas of Tanzania in order to increase the 
evidence available to make sensible decisions on antimicrobial therapy both at the 
level of the practicing clinician and at the level of authorities responsible for 
developing guidelines.   
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3. Aims of the study 
The aims of the study were: 
- To implement and evaluate a computerized system for surveillance of 
antimicrobial resistance at MUCHS. 
- To determine the prevalence of various pathogenic bacteria, fungi and malaria 
parasites as etiological agents in bloodstream infections in infants and children 
presenting with fever at MUCHS.  
- To describe the susceptibility patterns of the isolated pathogenic bacteria and 
the presence of specific resistance problems such as MRSA and ESBL. 
- To assess any impact of HIV co-infection on the prevalence and antimicrobial 
susceptibilities of the causative agents. 
- To assess the impact of resistant bacteria on the patient outcome. 
- To evaluate the microbial etiology and resistance patterns in pediatric 
meningitis cases at Haydom Lutheran Hospital. 
- To assess the microbial etiology and susceptibility patterns bacteriuria in 
pregnant women in Mbulu and Hanang district.  
- To compare antimicrobial resistance data from urban and rural areas of 
Tanzania.  
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4. Study population and methods 
4.1 Study settings 
The studies were performed in two areas of Tanzania. Papers 1, 2 and 3 are based on 
work from Muhimbili University College of Health Sciences (MUCHS) in the 
commercial capital, Dar es Salaam, and papers 4 and 5 are based on work done in and 
around Haydom Lutheran Hospital in a rural area in Manyara Region, Northern 
Tanzania. Microbiological investigations were done at the Department of 
Microbiology and Immunology, MUCHS, at Institute of Medicine, University of 
Bergen, Norway and at Department of Microbiology, Ullevål University Hospital, 
Oslo. 
4.1.1 Tanzania 
The country comprises 945 090 square kilometer. It has an estimated population of 
34.4 million and an annual population growth rate of 2.9%. The official sizes of the 
populations of the two study areas are 2.5 million in the region of Dar es Salaam and 
1.0 million in Manyara region (www.tanzania.go.tz/census/). Eighty percent of the 
population is employed in agricultural activities. Small-size (0.9-3.0 hectare) farms 
dominate the agricultural sector. Seventy percent of farmland is cultivated by hoe, 
20% by ox-plough and only 10% by tractor. The agricultural production suffers from 
poor farming tools and a combination of unstable weather conditions and lack of 
irrigation facilities. The main staple crops are maize, sorghum, millet, rice, wheat, 
beans, cassava, bananas and potatoes. The main export crops are coffee, cotton, 
cashew nuts, tobacco, sisal, pyrethrum, tea, cloves, other spices and flowers. 
Tanzania is considered one of the economically poorest countries in the world with 
an estimated per capita income at only 330 USD in 2005 (www.worldbank.org). 
Tanzania spends 12 USD per capita on health annually, or an estimated 4.1% of the 
GDP [4]. The country has prioritized primary health care and has excellent coverage 
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of the childhood immunization program. Lately, the net enrollment in primary school 
has increased considerably from 59% in 2000 to 95% in 2005. Although still high, 
there has been a significant decrease in infant mortality (from 100 to 68 per 1000 live 
births) and child mortality (from 156 to 112) from 2000 to 2004. Maternal mortality 
remains extremely high at 1.5% of all births (compared to 0.006% in Norway), and 
the country has a high burden of the major infectious diseases such as malaria, 
tuberculosis (estimated incidence 371 pr 100,000) [106] and HIV infection (estimated 
prevalence of 7% of the population) [107]. Currently the estimated life expectancy at 
birth is only 46 years. The country has 8 consultant/specialized hospitals, of which 4 
are government run. There are 17 regional hospitals (all government) and 68 district 
hospitals (55 government). 479 health centers (409 government) and more than 3955 
dispensaries (2450 government). 
4.1.2 Dar es Salaam, MUCHS 
With more than 1000 beds Muhimbili National Hospital / MUCHS is the largest 
hospital in the country, serving as a national referral and university teaching hospital, 
as well as a primary and referral hospital for the population in the Dar es Salaam area. 
Dar es Salaam is expanding rapidly under the influx of people from other parts of the 
country and abroad. The Department of Microbiology and Immunology at MUCHS 
analyses specimens from inpatients and outpatients at the hospital, as well as 
specimens from a number of nearby situated hospitals. The Department of Pediatrics 
has a neonatal section (Ward 36), two wards for general pediatrics (ward A and B), 
one ward mainly for gastroenteritis (ward 17) and a ward for malnutrition (Makuti). 
Only patients aged 0 to 7 years are admitted to the pediatric wards. The most 
commonly used antimicrobial treatment regimens for common infections are 
presented in Table 2, and the dosages used in Table 3 (these tables were not presented 
in the articles).
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Table 2.  Treatment regimens for bacterial infections in infants* and children† at MUCHS 
Diagnosis Drugs (administration route ‡) Duration (days) 
Septicemia * Ampicillin (iv) + cloxacillin (iv) + gentamicin (iv) 
† Benzyl penicillin (im/iv) + gentamicin (iv) 
† Benzyl penicillin (im/iv) + chloramphenicol (iv) 
5 – 10 
depending on 
the severity 
Meningitis * Ampicillin (iv) + cloxacillin (iv) + gentamicin (iv) 
† Benzyl penicillin (im/iv) + chloramphenicol (iv) 
14 - 21 
Pneumonia * Ampicillin (iv) + cloxacillin (iv) + gentamicin (iv) 
† Benzyl penicillin (im/iv) + gentamicin (iv) 
7 - 10 
Upper respiratory tract 
infections, sore throat, ear 
infections 
Amoxicillin (po), erythromycin (po) or cephalexin (po) 5 - 7 
Skin infections 
 
Phenoxymethyl-penicillin (po), cloxacillin (po), 
erythromycin (po) or cephalexin (po) 
5 - 7 
Osteomyelitis Ampicillin (iv) + cloxacillin (iv) + gentamicin (iv) 6 weeks 
Urinary tract infection Co-trimoxazole (po), ampicillin (po), amoxicillin-
clavulanate (Augmentin) (po) 
 
Severe urinary tract infection Ampicillin (iv) + gentamicin (iv) 7 - 14 
Necrotizing enterocolitis Ampicillin (iv) + gentamicin (iv) 
Ampicillin (iv) + chloramphenicol (iv) 
Gentamicin (iv) + metronidazol (iv) 
7 - 14 
Suspected staphylococcal 
infection (skin, surgery, late 
onset sepsis) 
Cloxacillin (iv/po) + gentamicin (iv) 14 
* Infants. † Children ≥ 1 month. ‡ po = oral, im = intra-muscular, iv = intra-venous. In addition, there is 
occasional use of cefuroxime, cefotaxime, ceftriaxone, and amikacin 
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During the year 1997-98 the neonatal ward admitted 7,236 patients and ward A + B 
together admitted 7,241 patients. The department has a total of 120 beds and 70 cots. 
There are approximately 30-40 deliveries per day at the hospital, out of which 
Table 3.  Dosage schedules for commonly used antimicrobial agents in children at MUCHS 
Drug (administration route*) Total daily dose Number of doses per 24 hours 
 (mg/kg) Age <= 1 week Age > 1 week 
Benzyl-penicillin (iv) 100 - 200 2 3 
Phenoxymethyl-penicillin (po) 25 - 50 4 4 
Ampicillin (po, im, iv) 50 - 200 2 3 
Amoxicillin (po) 20 – 40 3 3 
Amoxicillin clavulanate (po) 20 – 40 3 3 
Cloxacillin (po, iv) 100 2 3 
Cephalexin (po) 25 – 100 4 4 
Cefuroxime (iv) 50 – 240 2 2 
Cefotaxime (im, iv) 50 – 180 4 4 
Ceftriaxone (im, iv) 50 – 100 2 2 
Erythromycin (po) 20 - 40 3 3 
Co-trimoxazole (po) 8 / 40 2 2 
Gentamicin (iv) 5 1 1 
Gentamicin (iv) † 2.5 1 2 
Amikacin (iv) 15 1 1 
Amikacin (iv) ‡ 20 1 1 
Chloramphenicol (iv) 50 2 3 
Chloramphenicol (iv) † 25 1 1 
Metronidazole (po, iv) 15 2 3 
* po = oral, im = intra-muscular, iv = intra-venous. † Low birth weight. ‡ Below 1 year of age 
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approximately 20% are done by cesarean section. The resources available in the 
pediatric department include nutrition via nasogastric tube, IV/IM administration of 
drugs, blood transfusions, phototherapy, oxygen treatment with mask and 
electrocardiography. A CPAP machine was available, but was out of order by the 
time of the study. Respirators and cardiopulmonary surveillance are not available.  
4.1.3 Haydom Lutheran Hospital, Mbulu and Hanang 
The study of urinary bacterial pathogens was undertaken at antenatal care visits 
through eleven outreach clinics run by Haydom Lutheran Hospital and one stationary 
clinic at the hospital [108]. Dongobesh and Basotu, in Mbulu and Hanang districts, 
respectively, are typical rural areas in Manyara region (previously part of Arusha 
region) in northern Tanzania. The major causes of stillbirths and perinatal mortality 
in the study area are infections (39%), particularly malaria and pneumonia, as well as 
asphyxia (24%) and immaturity (15%) [109]. The HIV-sero-prevalence in the study 
area was low, only 0.3% and 0.4%, respectively, in two studies from 1996 and 1998 
[110]. Haydom Lutheran Hospital is situated 300 km from Arusha, which is the 
nearest major city. The outreach clinics, located five to one hundred kilometers from 
Haydom Lutheran Hospital were visited on a monthly basis. 
4.2 Study populations 
The WHONET surveillance study (paper 1) was a laboratory-based study, in which 
all bacterial isolates of clinical significance, a total of 7617 isolates, from specimens 
received at MUCHS during the period July 1st 1998 to December 31st 1999 were 
recorded and analyzed. The specimens examined included urine, pus/secretions 
(swabs from skin, surgical and traumatic wounds, burns, umbilical cords, throat, 
nose, eye and ear discharge and genital swabs), blood, cerebrospinal fluid, other body 
fluids, stools and other specimens. Mycobacteria and anaerobic bacteria were not 
included in the study.  
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The study population in the bloodstream infection study (paper 2) consisted of 
consecutively admitted patients who upon admission to the pediatric department at 
MUCHS had temperature instability or other signs or symptoms of serious systemic 
infection, such as sepsis, meningitis, pneumonia, typhoid etc. A total of 1787 patients 
were enrolled, corresponding to 1828 admissions.  
The study population in the study on ESBL-producing bacteria (paper 3) was a subset 
of the study population in the bloodstream infection study (paper 2), and included all 
children who had E. coli, Klebsiella spp. or salmonella isolated from their blood 
cultures, corresponding to a total of 113 children. 
The study population of the meningitis investigation (paper 4) included 24 children 
with suspected meningitis and/or septicemia, out of a total of 360 children, who were 
admitted at Haydom Lutheran Hospital from July to August 2000.  
The study population in the bacteriuria study (paper 5) included 5153 pregnant 
women consecutively enrolled between mid-April 1995 and mid-March 1996 as they 
attended antenatal care visits through eleven outreach clinics and one stationary clinic 
run by Haydom Lutheran Hospital [108]. The majority of the study subjects (n=3715) 
were residents of two divisions, Dongobesh and Basotu, in Mbulu and Hanang 
districts, and the study covered an estimated 68% of the pregnant women in those two 
divisions [108]. 
4.3 Study designs 
The WHONET surveillance study (paper 1) was a laboratory-based prospective, 
observational cohort study, and a qualitative evaluation of the intervention of  
introducing a computerized surveillance system at MUCHS. 
The bloodstream infection study (study 2 & 3) was a prospective, observational 
cohort study with consecutive inclusion of study subjects suspect of having systemic 
infection. In both papers, nested case-control designs within the cohort of the main 
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study were used to assess risk factors for infection caused by bacteria with certain 
resistance traits, and risk factors for adverse outcome. 
The investigation of the meningitis cases at Haydom Lutheran Hospital (paper 4) was 
an outbreak investigation as part of the quality assurance of medical services at the 
hospital. The design of a prospective, observational cohort study was used to assess 
the association between salmonella meningitis and fatal outcome. 
The study of bacteriuria in pregnant women (paper 5) was a prospective, 
observational cohort study including consecutively pregnant women attending 
antenatal clinics. A nested case-control design within the main cohort was used to 
assess the impact of bacteriuria and antimicrobial resistance on outcome of the 
pregnancy. 
4.4 Methods 
4.4.1 Specimen collection, transport and bacterial isolation 
In the WHONET surveillance study (paper 1), microbiological specimens were 
obtained as part of the routine diagnostic services in accordance with regular practice 
at the hospital.  
In the bloodstream infection study (paper 2 and 3), blood specimens (1 ml from 
neonates, 5 ml from older children) were inoculated bedside in BACTEC Myco/F 
lytic blood culturing vials (Becton Dickinson, Franklin Lakes, NJ). Positive blood 
cultures were subcultured on Columbia II agar base (Oxoid Ltd, Basingstoke, UK) 
with five percent human blood, chocolate agar and MacConckey agar (Difco/BD 
Diagnostic Systems, Sparks, MI, USA). The culturing vials also support the growth 
of M. tuberculosis and other mycobacteria.  
In the meningitis investigation (paper 4), blood and spinal fluid specimens were 
inoculated in BBL SeptiChek blood-culture bottles (Becton Dickinson, Sparks, MD 
USA) and on locally prepared non-selective Thayer-Martin medium in slanted tubes, 
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respectively. All cultures were incubated at 35˚C for 5 days and inspected daily for 
bacterial growth. Positive bacterial specimens were shipped to University of Bergen, 
Norway, for further study.  
In the bacteriuria study (paper 5), ‘clean-catch’ midstream urine specimens were 
collected in pre-boiled and air-dried plastic containers. Part of the specimen was 
inoculated immediately using the Uricult ® dip slide (Uricult ®, Orion Diagnostica, 
Espoo, Finland). The dip slides were transported to the hospital within 2-9 hours and 
incubated at 37˚C for 18-24 hours. Significant bacteriuria was defined as growth of 
more than 100,000 colony-forming units per ml of one or two bacterial isolates [21, 
22]. The remaining urine was examined for leukocyte esterase, nitrite, blood, albumin 
and glucose using a reagent strip (Nephur-Test ® + Leuco, Boehringer Mannheim 
Gmbh, Mannheim, Germany). Positive dip slides were sent to Norway for further 
microbiological investigations. 
4.4.2 Identification 
Bacterial isolates were identified using standard laboratory methods [111, 112], 
including the use of API20E, API20NE and API 20 AUX systems (bioMérieux SA, 
Marcy l’Etoile, France). The identify of isolates of enterococci and S. aureus were 
confirmed by PCR [113]. 
4.4.3 Susceptibility testing 
The antimicrobial susceptibilities of the bacterial isolates were examined by disk 
diffusion methods. In the WHONET surveillance study (paper 1), disk diffusion 
testing was done according to the Stokes’ method [114] on Iso-Sensitest (Oxoid 
Limited, Basingstoke, UK) agar plates. In the bloodstream infection study (paper 2 & 
3), disk testing was done according to CLSI (NCCLS) guidelines [115]. In the 
meningitis investigation (paper 4) and the bacteriuria study (paper 5) disk testing was 
done according to Scandinavian guidelines on PDM medium (AB Biodisk, Solna, 
Sweden) [116]. In the bloodstream infection study (paper 2 & 3) Gram-negative 
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isolates from blood cultures with reduced susceptibilities to cefotaxime (zone 
diameter <27mm) and/or ceftazidime (zone diameter <22mm) according to guidelines 
for laboratory detection of ESBL from the Centers for Disease Control and 
Prevention (http://www.cdc.gov/ncidod/hip/Lab/FactSheet/esbl.htm) were tested for 
ESBL phenotype with three different Etest ESBL strips, ceftazidime / ceftazidime + 
clavulanate, cefotaxime / cefotaxime + clavulanate and cefepime / cefepime + 
clavulanate (AB Biodisk, Solna, Sweden). 
4.4.4 Detection and characterization of resistance genes 
In the bloodstream infection study (paper 2 & 3), we used a multiplex PCR to 
confirm the presence of the mecA gene conferring methicillin resistance and the nuc 
gene, which verifies that the isolate is a S. aureus [113, 117]. Isolates with ESBL 
phenotype were examined for the presence of blaTEM, blaSHV and blaCTX-M by PCR 
[118-120]. The PCR products were sequenced with the ABI PRISM BigDye cycle 
sequencing ready reaction kit (PE Biosystems, Norwalk, CT) using the same primers. 
The products were analyzed on an ABI PRISM 3700 DNA sequencer (PE 
Biosystems). Sequences were aligned with known ESBL sequences 
(www.lahey.org/studies/) using Vector NTI version 6 (Informax, Frederick, 
Maryland, US). 
4.4.5 Evaluation of relatedness of bacterial isolates 
Gram-negative isolates from the bloodstream infection study (paper 2 & 3) and the 
meningitis investigation (paper 4) were explored with amplified fragment length 
polymorphism [121]. Salmonella isolates from meningitis investigation (paper 4) 
were also genotyped by pulsed-field gel electrophoresis. 
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4.4.6 Resistance surveillance 
The WHONET software, available free-of-charge from WHO [122], was 
implemented and used for the surveillance of antimicrobial resistance at MUCHS 
(paper 1). 
4.4.7 Statistical methods 
The WHONET software was used for entry and preliminary analysis of microbiology 
data (paper 1, 2 & 3). We used Stata 8.0 for Macintosh (Stata Corporation, College 
Station, Texas, USA) for further analysis of data. Assessment of differences of 
proportions and univariate assessment of risk factors for intra-hospital death was 
done by Fisher’s exact test with a two-sided P-value and odds ratios, and 95% 
confidence intervals were obtained by the ‘logistic’ function in Stata. Multivariate 
analysis (papers 2 & 3) was performed by automated and manual backwards step-
wise logistic regression where factors with P>0.2 were removed from the model. 
Comparisons of medians of time variables were done by Wilcoxon rank-sum (Mann-
Whitney) test. Outcome data on intrahospital death was also evaluated by Kaplan-
Meyer survival analysis.  
4.5 Ethical considerations 
The WHONET surveillance study (paper 1) was a laboratory-based exercise with an 
aspect of quality assurance and did not involve any intervention concerning the 
patients directly. It was not deemed necessary to seek ethical clearance for this study. 
The study of pediatric bloodstream infections (paper 2 & 3) was performed as part of 
the regular laboratory support for the pediatric department. Informed consent from 
the patient’s parents or responsible family member was obtained before taking blood 
for microbiological investigations when feasible. The Tanzanian national language, 
Kiswahili, was used for obtaining consent using consent forms. When patients were 
critically ill with suspected sepsis or meningitis, a blood specimen was taken based 
Bjørn Blomberg 45 
on oral consent, since these investigations are strongly recommended as routine test 
in such situations, and since it may be unethical and inappropriate to waste time on 
paperwork in such situations. In such cases, written consent was obtained in 
retrospect. When patients’ parents did not accept HIV testing, they were allowed to 
opt out for HIV testing and still be included for bacteriological investigations. The 
Muhimbili University College of Health Research Ethics Committee approved the 
study protocol. The protocol was also submitted to the Regional Committee for 
Ethics in Medical Research for Western Norway (previously REK III, now REK 
Vest), which gave a preliminary recommendation for the study. 
The meningitis investigation (paper 4) was a case investigation requested by the 
hospital as part of the quality assurance of the medical services and, as such, did not 
need ethical clearance. 
The bacteriuria study (paper 5) was approved by the Commission for Science and 
Technology (COSTECH) in Tanzania and the Regional Committee for Ethics in 
Medical Research for Western Norway (REK III/ REK Vest). Participation in the 
study was voluntary. Study subjects received free treatment with nitrofurantoin if 
they had asymptomatic bacteriuria or urinary tract infection. 
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5. Main results of the studies 
5.1 Paper 1 – The resistance surveillance study 
The paper describes the implementation of a computerized system for surveillance of 
antimicrobial resistance. The WHONET software was well suited to enter and 
analyze data on a large number of bacterial isolates. The study evaluated more than 
7500 bacterial isolates, of which 10% were from blood cultures, and over 40% each 
from pus and urine cultures. Gram-negative bacteria showed relatively high rates of 
resistance to most antimicrobial drugs, except for fluoroquinolones, gentamicin and 
third-generation cephalosporins. The software was free-of-charge, thus, the direct 
cost of implementing the surveillance system was small, limited to the purchase of a 
basic computer, as well as some basic training activities. The running cost of the 
surveillance program was limited to human sources for operating the software, 
minimum 50% of a laboratory technician position. An important aspect of a 
surveillance system is its function as a quality assurance tool and its ability to attract 
focus on laboratory issues which need to be improved. Susceptibility data would give 
more information if results were recorded as inhibition zone diameters instead of 
interpreted values (“R”, “I” or “S”). Furthermore, it was highlighted that the 
surveillance system is dependent on susceptibility testing of acceptable quality. While 
quality susceptibility testing may incur extra costs, surveillance data may improve 
empiric therapy for infections and contribute to containing or reducing antimicrobial 
resistance, which in the long term may help reducing morbidity and mortality, and 
diminish the need for expensive second-line antimicrobial agents and thus save lives 
and reduce suffering.  
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5.2 Paper 2 – The study of bloodstream infections 
This paper describes the prospective observational cohort study of bloodstream 
infections in 1828 admissions of children aged 0-7 years. As expected in a cohort of 
children with suspected systemic infection, almost all (94%) received antimicrobial 
therapy. Table 1 in Paper 2 (Annex) shows details on the antibiotic consumption in 
the study population. Table 4 (not presented in the article) shows the market shares of 
the most common antimicrobials as estimated from a survey of 15 randomly selected 
pharmacies in Dar es Salaam (not shown in Paper 2) [123]. The prices of commonly 
used antimicrobial formulations are shown in table 5 (not presented in the article). 
The survey was done in September 2000 by two Norwegian medical students 
attached to our project using a questionnaire in Kiswahili, which was completed and 
returned anonymously by the pharmacist. 
Table 4. Sales of antimicrobial drugs (percentage of total defined daily doses (DDD) sold) from 
15 randomly selected pharmacies in Dar es Salaam in September 2000. 
Penicillin 2.8% 
Ampicillin, amoxicillin 23.1% 
Cloxacillin 8.8% 
Cephalosporins 0.04% 
Tetracycline 19.8% 
Erythromycin, and other macrolides 9.1% 
Co-trimoxazole 5.2% 
Trimethoprim 4.6% 
Quinolones 14.2% 
Aminoglycosides 1.3% 
Chloramphenicol 1.3% 
Metronidazole 8.6% 
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Table 5. Cost of antimicrobials per defined daily dose (DDD 
Drug sales at pharmacies Form DDD (mg) TSH pr DDD Euro* pr DDD 
Nitrofurantoin Tab 200 30 0.003 
Tetracycline Caps 1000 60 0.006 
Co-trimoxazole Tabs 2000 62.5 0.064 
Metronidazole Tabs 1500 75 0.075 
Amoxicillin Caps 1000 160 0.160 
Erythromycin Tabs 1000 200 0.200 
Ampicillin Caps 2000 280 0.280 
Penicillin Tabs 2000 280 0.280 
Cloxacillin Caps 2000 320 0.320 
Ampicillin+cloxacillin Caps 2000 400 0.400 
Chloramphenicol Caps 3000 420 0.420 
Ciprofloxacin Tabs 1000 600 0.600 
Azithromycin Caps 300 900 0.900 
Nalidixic acid Tabs 4000 1200 1.200 
Amoxicillin-clavulanate Tabs 1000 2000 2.000 
Cefalexin Caps 2000 2000 2.000 
Cefaclor Caps 1000 4000 4.000 
Penicillin Inj 3600 450 0.450 
Gentamicin Inj 240 750 0.750 
Chloramphenicol Inj 3000 1800 1.800 
Ampicillin Inj 2000 2000 2.000 
Cefuroxime † Inj 3000 31200 31.200 
*The exchange rate for Euro to Tanzanian shillings at the time was roughly estimated 1:1000. 
†Third-generation cephalosporins were not available from the pharmacies surveyed, but were 
generally more expensive than cefuroxime, which was the most costly drug among those available. 
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These figures from the market survey agree with the antibiotic consumption data in 
paper 2, if we take into account that the sales figures incorporate antimicrobial use in 
adults (tetracyclines and fluoroquinolones) as well as children. 
The incidence of laboratory-confirmed bloodstream infection was 13.9% (255/1828) 
of admissions. The most frequent isolates were Klebsiella spp., salmonellae, E. coli, 
enterococci and S. aureus.  Furthermore, 21.6% had malaria and 16.8% HIV 
infection. One third (34.9%) of the children with laboratory-confirmed bloodstream 
infection died. The case-fatality rate from Gram-negative bloodstream infection 
(43.5%) was more than double that of malaria (20.2%) and Gram-positive 
bloodstream infection (16.7%). Significant risk factors for death by logistic 
regression modeling were inappropriate treatment due to antimicrobial resistance, 
HIV infection, other underlying infectious diseases, malnutrition and bloodstream 
infection caused by Enterobacteriaceae, other Gram-negatives and candida. The study 
shows that bloodstream infection was less common than malaria, but caused more 
deaths. The finding that antimicrobial resistance, HIV-infection and malnutrition 
predict fatal outcome calls for renewed focus on stopping the further emergence of 
resistance, improving HIV care and nutrition for children. 
5.3 Paper 3 – The ESBL study 
This paper describes a nested case-control study within the cohort of the study of 
bloodstream infections (paper 2) examining patients with bloodstream infections 
caused by ESBL-producing strain of the three most common species of 
Enterobacteriaceae. ESBL was present in high proportions of E. coli (25% [9 of  
36]), Klebsiella pneumoniae isolates (17% [9 of 52]) and one isolate of salmonella (S. 
Newport) causing pediatric septicemia at MUCHS. Patients with septicemia due to 
ESBL-producing organisms had a significantly higher fatality rate than those with 
non-ESBL isolates (71% versus 39%, P =0.039). This is the first report of the CTX-
M-15 genotype of ESBLs on the African continent and the first observation of SHV-
12 genotype in an isolate of Salmonella enterica serotype Newport. The study 
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demonstrates that the spread of ESBL-producing bacteria has extremely serious 
implications in a resource-constrained hospital in Sub-Saharan Africa. 
5.4 Paper 4 – The meningitis investigation 
This paper describes the microbiological investigation of an outbreak of pediatric 
meningitis with unusually high case-fatality rate at a rural hospital in northern 
Tanzania. We established a provisional microbiology laboratory, obtained blood and 
spinal fluid specimens, which were cultured. Among 24 children with suspected 
meningitis and/or septicemia, five neonates had meningitis caused by Salmonella 
enterica serotype Enteritidis, all of whom died. Two children had S. Enteritidis 
septicemia without meningitis and both survived. Genotyping with pulsed-field gel 
electrophoresis suggested a clonal outbreak. The salmonella strain was resistant to 
ampicillin and sensitive to gentamicin, the two drugs commonly used to treat 
neonatal meningitis at the hospital. The investigation reaffirms that nontyphoid 
salmonellae can cause meningitis associated with very high case-fatality rates. 
Resistance to multiple antimicrobial agents increases the risk of treatment failure and 
may have contributed to the fatal outcome in all of the five patients with salmonella 
meningitis. The investigation indicated that the outbreak was nosocomial and the 
outbreak subsided after hygienic measures were instituted. The study demonstrates 
that it is practical and valuable to establish provisional microbiological services to 
investigate and control disease outbreaks even in remote rural areas.  
5.5 Paper 5 – The study of bacteriuria in pregnant women 
This study describes the prevalence and antimicrobial susceptibility of bacteria 
causing bacteriuria in pregnant women in a rural area in Northern Tanzania. Urine 
specimens from 5153 pregnant women were inoculated on dip slides, and a total of 
101 positive dip slides were identified and tested for susceptibility to antimicrobial 
agents by disc diffusion. The most frequent isolates were E. coli (n=27) and 
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enterococci (n=15). E. coli isolates showed low rates of resistance to ampicillin 
(17%), mecillinam (9%), cefalexin (0%), nitrofurantoin (4%), trimethoprim-
sulfamethoxazole (0%), trimethoprim (13%) and sulfamethoxazole (0%), while other 
Gram-negative bacteria displayed higher rates of antimicrobial resistance. All 
enterococcal isolates were sensitive to ampicillin. Bacteriuria with E. coli was 
correlated with adverse outcome of pregnancy (relative risk 4.13, 95%CI: 1.50-
11.38). This study shows that urinary isolates of E. coli and enterococci from rural 
areas of northern Tanzania are more frequently susceptible to antimicrobials than 
isolates from urban areas such as Dar es Salaam. The findings suggest that 
susceptibility data from both rural and urban areas should be taken into account when 
planning antibiotic policies.  
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6. Discussion 
6.1 Surveillance of antimicrobial resistance 
Surveillance of antimicrobial susceptibility of clinical bacterial isolates is important 
to guide empiric therapy of bacterial infections. The surveillance study showed that it 
is feasible and inexpensive to implement a computerized surveillance system at the 
level of a tertiary hospital in Sub-Saharan Africa. Appropriate software such as 
WHONET is available free-of-charge [122]. In a laboratory, which already performs 
susceptibility testing, only a minimal extra investment for a computer and running 
costs for a technician to operate the software can result in the accumulation of highly 
useful information on antimicrobial susceptibility.  
While determination of MIC values would be more accurate, the higher cost and 
associated workload makes it an unfeasible option for routine surveillance activities. 
Thus, disk diffusion testing is generally used for surveillance, and is probably the 
only method that is feasible for routine use, at lest in a developing country setting. 
Unfortunately, disk diffusion testing is far from standardized internationally, and 
worldwide there are at least twelve different in vitro methods in use, and only in 
Europe the number is at least ten [124]. To further complicate the issue, there are 
ongoing changes in the interpretive criteria for susceptibility testing [125]. Yet, 
routine susceptibility testing data are regarded suitable for surveillance even if 
obtained with different methods [126]. 
One of the most important aspects of the surveillance system is to alert the 
professionals of particular emerging resistance-problems, and to kick off targeted 
research on these topics. Indeed, the WHONET surveillance study identified 
resistance in Klebsiella spp. and other Gram-negatives as a particular problem, and 
communication with the pediatricians strengthened the suspicion that these resistant 
Gram-negative organisms were of great clinical importance. On this background, we 
decided to do a prospective study on bloodstream-infections in children as described 
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in Papers 2 & 3. While routine surveillance is performed with the relatively 
inexpensive disk diffusion method, prospective studies targeting crucial problems 
such as bloodstream infections justifies the use of more accurate methodology, 
including MIC determination and molecular methods to describe the problem as 
detailed as necessary.   
Other positive developments associated with the surveillance activities were: 1) 
opportunities to create awareness about antimicrobials resistance issues, 2) 
establishment of a chapter of APUA (Alliance for the prudent use of antibiotics, 
www.apua.org) in Tanzania, 3) identification of opportunities for further 
improvements in the surveillance testing methodology. The laboratory was using 
Stokes’ method for disk diffusion testing [127], which relied on visual interpretation 
of the difference in inhibition zones between the clinical isolate and the control strain. 
This method is robust in the case of using non-standard, in-house made antibiotic 
discs of uncertain strength.  However, provided quality reagents are available, a 
method such as the one recommended by the CLSI (NCCLS) and others [115] would 
have advantages and allowing for more sophisticated analysis of data, such as the 
detection of gradual shifts in antibiotic susceptibility and opportunities for early 
warning of emerging resistance problems. 
6.2 Resistance patterns 
The routine surveillance (paper 1) indicated that Gram-negative bacilli frequently 
were resistant to commonly used antibiotics, as reported in the region [99, 100, 128, 
129] and elsewhere [130], and that a smaller proportion of E. coli (5%), Klebsiella 
spp. (6%) and Enterobacter spp. (10%), but no salmonella (0%) were resistant to 
third-generation cephalosporins. In the study of bloodstream infections (paper 2 & 3), 
more in debt investigation with Etest, PCR and DNA sequencing revealed a high 
proportion of ESBL-producers among common Gram-negative isolates, 18% of the 
Enterobacteriaceae isolates (E. coli 9/37, Klebsiella spp. 9/53, Enterobacter spp. 5/9, 
salmonella 1/39 and Pantoea spp 2/2) involving TEM-63, SHV-2a, SHV-12 and 
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CTX-M-15 genotypes, and in 3 isolates of non-Enterobacteriaceae (one 
Acinetobacter spp. and the 2 Chryseobacterium spp.). 
Our study was the first report of TEM, SHV and CTX-M or other types of ESBL-
producing bacteria in Tanzania, and one of few reports on ESBL-type resistance from 
Sub-Saharan Africa [118, 131-138], although others have followed [139-145]. 
The proportions of ESBL-producing Enterobacteriaceae in our study was higher than 
those reported from South Africa [133] and comparable to ESBL-affected institutions 
in US, Taiwan, mainland China and Japan [38]. CTX-M-15 had been found in India, 
Japan, Europe and elsewhere [146], however, our study was the first report of CTX-
M-15 genotype on the African continent, although CTX-M-12 had previously been 
reported in K. pneumoniae isolates from Kenya [118]. Our study was also the first 
report of SHV-12 type ESBL in an isolate of Salmonella Newport. Recently, SHV-
12-like ESBL was reported in isolates of S. Enteritidis and S. Babelsberg obtained in 
France from several children adopted from one particular orphanage in Mali [136]. 
However, apart from this, our report was the first account of SHV-12 genotype ESBL 
from Sub-Saharan Africa. Gentamicin-resistance is common in ESBL-producing 
Gram-negative bacteria, sometimes in as much as 96% of isolates [147]. In our study, 
ESBL-producers showed a high degree of resistance to gentamicin, chloramphenicol, 
doxycycline and trimethoprim-sulfamethoxazole.  
The surveillance study indicated a very low prevalence of MRSA, consistent with 
previous data from the same hospital [148, 149], and this was confirmed with PCR 
for the mecA gene in the bloodstream infection study. 
The surveillance study revealed relatively low prevalence of enterococci compared to 
studies from high-income countries [150], and suggested a low rate of ampicillin-
resistant enterococci (ARE). However, the bloodstream infection study revealed high 
rates of combined ampicillin-resistant and high-level gentamicin-resistant (HLGRE) 
E. faecium and HLGRE E. faecalis.  
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While other countries in the region have been affected by penicillin-resistant 
pneumococci [151, 152], the surveillance study (paper 1) indicates that pneumococcal 
disease in Dar es Salaam can safely be treated with penicillin.  
6.3 Trends of antimicrobial susceptibility 
While resistance to ampicillin, tetracycline and sulfonamides in Gram-negative 
bacteria was frequent already in the seventies [96, 97], it is worrying, but not 
unexpected, that resistance to trimethoprim-sulfamethoxazole, chloramphenicol, and 
other drugs appear to have increased compared to previous studies [97, 98]. The 
extensive use of chloramphenicol for the treatment of presumed cases of typhoid 
fever and the use of trimethoprim-sulfamethoxazole for the ambulatory treatment of 
chest infections, malaria and, not least, for prophylaxis in people with HIV, may have 
contributed to the high prevalence of resistance to these two drugs.  
The increasing rate of gentamicin-resistance in Enterobacteriaceae is worrying, 
considering the importance of this drug in the treatment of bloodstream infections. 
Gentamicin-resistance in E. coli has increased from zero in 1978-79 [97] to 2% in 
1995 [98] , 8% in the surveillance study (paper 1), and 29% and 46% in community-
acquired and hospital-acquired bloodstream infections, respectively (paper 2). Similar 
increases in gentamicin-resistance in E. coli has been noted in neighboring Kenya 
[99, 153].  In Klebsiella spp., which are inherently resistant to ampicillin, gentamicin-
resistance is even more alarming and has reached almost 50% in both community- 
and hospital-acquired infections, which means that half of the cases of bloodstream-
infection caused by Klebsiella spp. at the hospital will not have any effect of the 
commonly given combination of ampicillin and gentamicin. 
While tetracyclines are not recommended for children, it is interesting to observe the 
decline in tetracycline resistance in S. aureus from in 57% in 1979 and 74% in 1982 
[148] to 49% in 1998-99 (paper 1) and 38% in community-acquired infections in 
2001-02 (paper 2), although hospital-acquired S. aureus showed 65% resistance. In 
the late seventies, huge quantities of tetracycline was used to prevent and treat 
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Cholera in Tanzania; as much as 1788 kilograms of tetracycline were used during a 
period of only 5 months [154]. As Vibrio cholerae developed tetracycline-resistance, 
the drug was much less used, which may have influenced resistance rates in other 
species, such as S. aureus. 
6.4 Community-acquired and nosocomial infections 
Among patients coming to the hospital, there may be of selection of patients with 
infections caused by resistant microbes, since many patients rely on health centers 
and pharmacies to cure simple ailments, and only come to the hospital when primary 
treatment fails. The study identified only a few resistance traits, which were more 
common in hospital-acquired infections (or inpatients), such as resistance to 
ampicillin (paper 1) and amoxy-clavulanate and cephalosporins (paper 2) in E. coli 
and resistance to gentamicin (paper 1) and co-trimoxazole (paper 1 & 2) in Klebsiella 
spp.. Kaplan-Meier survival graphs showed that deaths in patients with septicemia 
due to ESBL-producing bacteria occurred later than those caused by non-ESBL-
producing isolates. Time from admission to blood culture was a significant risk factor 
for infection with ESBL. The majority (6/7) of TEM-63-producers were isolated from 
nosocomial infections, and the three TEM-63-producing isolates of Klebsiella spp. 
were virtually identical on genotyping with amplified fragment length polymorphism. 
These findings indicate nosocomial spread.  However, half (3/6) of CTX-M-15-
producers and almost two-thirds (9/15) of SHV-12 were from community-acquired 
infections, indicating that ESBL-producers are a problem in the community as well. 
ESBL genes of the TEM, SHV and CTX-M families can reside in conjugative 
plasmids [38, 118, 119, 155, 156], and this has recently been demonstrated for CTX-
M-15 [146, 157]. Previous reports have demonstrated that ESBL genes can spread via 
epidemic strains, but also by plasmid dissemination between unrelated strains [158]. 
One study found the same ESBL gene (TEM-24) in as many as 4 different species of 
Enterobacteriaceae in one single patient, indicating that horizontal transfer of ESBL-
genes occurs in vivo at a considerable rate [89, 90]. The presence of identical ESBL 
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genotypes in multiple bacterial species in the current study, seems to support the 
notion that interspecies plasmid dissemination may contribute to the spread of ESBL 
in our setting also. 
Genotyping with pulsed-field gel electrophoresis suggested there was a clonal 
outbreak of bacteremia and meningitis caused by S. Enteritidis at Haydom Lutheran 
Hospital (paper 4). The genotyping information, the susceptibility patterns and the 
clinical information that all children with S. Enteritidis infections were born at the 
hospital and that the majority never left the hospital before they became ill, suggests 
that the outbreak was nosocomial. Nosocomial outbreaks of nontyphoid salmonella in 
neonatal wards is known from the literature [159]. Neonates are at particular risk of 
infection because of relatively reduced gastric acidity and peristalsis [12]. While 
medications, diagnostics, blood products, human milk, eggs and contaminated suction 
tubes have been sources of previous outbreaks [159, 160], the source of the outbreak 
at Haydom Lutheran Hospital was not established. However, despite unaltered 
antimicrobial treatment for meningitis at the hospital, the swift interventions with 
reinforcement of hygiene were followed by a drop in case-fatality rates from pediatric 
meningitis from >60% before the intervention to 40% by 2001 hospital annual 
reports.  
Further work on the Enterobacteriaceae isolates which produced SHV-12 [161], 
documented that resistance towards gentamicin (aac(3)-II gene), doxycycline, 
chloramphenicol and co-trimoxazole was transferred by the plasmid harboring ESBL-
gene blaSHV-12. This finding implies several important notions. First, resistance 
traits mediated by the same plasmid makes both the empiric first-line treatment 
regimen (ampicillin/penicillin + gentamicin) and the reserve regimen (ceftriaxone) 
for treatment of septicemia ineffective. Second, treatment with gentamicin, which 
generally is accepted as ecologically sound, may indeed contribute to the selection of 
ESBL-producing strains since the genes encoding for these different resistance traits 
are located on the same plasmid. Perhaps even more worrying, considering the high 
rates of HIV infection, is that the cheap co-trimoxazole, which is widely used as 
prophylaxis against opportunistic infections in HIV-infected persons, may contribute 
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to the selection of ESBL-producing strains. Likewise, chloramphenicol, the long-
standing drug of choice for the treatment of typhoid fever, is also frequently used and 
may contribute to selecting these ESBL-producers.   
6.5 Antimicrobial resistance in urban and rural areas 
It is reassuring, that E. coli isolates from the bacteriuria study in Northern Tanzania 
were highly susceptible to all tested drugs. Consequently, an important observation 
from this study is that antimicrobial resistance can vary considerably between rural 
and urban areas within a country. This should be taken into account when formulating 
antibiotic policies. In Tanzania, the great majority of the population lives in rural 
areas. Policies developed for urban areas may endorse the use of antibiotics, which 
are unaffordable for poor rural dwellers, including broad-spectrum antibiotics, which 
have the additional disadvantage of promoting further resistance. In countries with 
large rural populations, such as in Tanzania, resistance data from rural areas must 
play a significant role when deciding on antibiotic policies.  
6.6 Incidence of septicemia 
We found an incidence of septicemia of 13.9% (255/1828) of all admissions in the 
study. The incidence was higher in the youngest patients. For early-onset septicemia 
(within the first week of life) the incidence was 17.1%, for late-onset neonatal 
septicemia (week 2-4) 14.2% and for older children (>1month) 13.1%.  
Table 6 (not presented in the articles) shows an overview of published bacteremia 
studies from Sub-Saharan Africa. It is evident that there is great variation in reported 
incidences of bacteremia, ranging from 5.8% to 46.0%. The incidence reported from 
our study lies slightly lower than the median these studies.  
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Table 6. Incidence of bacteremia per hospital admission among African children. 
Location, period Incidence Population Ref. 
South Africa 5.8% (315/5397) All admitted children [162] 
Kilifi, Kenya 6.6% (1094/16570) All admitted children [8] 
Addis Ababa, Ethiopia 7.7% (49/634) Febrile children, 0-14years [163] 
Shongwe, South Africa 9.6% (31/323) Malnourished children [164] 
Ilesa, Nigeria 9.9% (15/152) Severely anemic children [165] 
Benin City, Nigeria 11.1% (71/642) Children (1m-5y) with acute fever [166] 
Nairobi, Kenya 12.1% (32/264) Febrile hospitalized children [167] 
Kigali, Rwanda 12.4% (112/900) Children with fever (≥39’) [129] 
Dar es Salaam, Tanzania 13.9% (255/1828) Children with suspected BSI† * 
Jos, Nigeria 15.6 (139/891) Children with suspected BSI† [168] 
Lwiro, D. R. Congo, 15.9% (124/779) All children admitted [169] 
Kampala, Uganda 17.1% (76/445) Malnourished children (<60 days) [170] 
Blantyre, Malawi 17.2% (365/2123) Children with fever [171] 
Kumasi, Ghana 20.3% (51/251) Children suspect of having malaria [9] 
Kigali, Rwanda 26.7% (36/135) Children having blood cultured  [172] 
Nairobi, Kenya 28.6% (26/91) Malnourished children, 2-60 months [173] 
Harare, Zimbabwe 30.7 (95/309) Age <8y, temp>38’, suspect infection [174] 
Nairobi, Kenya 31.7% (19/60) Children, clinical septicemia [175] 
Lagos, Nigeria 31.7% (19/60) Sicklers (hz), 3m-13y, with acute illness [176] 
Ibadan, Nigeria 38.2% (39/102) Febrile infants <1year [177] 
Bulawayo, Zimbabwe 43.4% (92/212) Children (0-5y), dead <3h before adm. [11] 
Ile-Ife, Nigeria 44.6% (54/121) Sick, young infants [178] 
Calabar, Nigeria 46.0% (552/1201) Children (0-15y), suspected BSI† [179] 
* Paper 2, †BSI = bloodstream infection 
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The incidence of septicemia among children admitted to hospitals is dependent on 
several factors including the health-care seeking behavior in the population, the type 
of study performed, the criteria for inclusion into the studies, antimicrobial use before 
blood-culture and the blood-sampling technique, transport time and culturing 
techniques. For instance, in the recent study from a rural hospital in Kilifi in 
neighboring Kenya, the incidence of community-acquired bacteremia was lower than 
in our study, 12.8% in children younger than 2months and 5.9% in older children [8]. 
However, the studies were designed differently with different inclusion criteria, 
which may explain this difference. In our study only patients admitted with features 
suggestive of infection were investigated while the Kenyan study included all 
children admitted to the hospital, except for children admitted for elective procedures. 
In resource-constrained settings, such as Sub-Saharan Africa, there are generally 
higher reported incidences of bacteremia in children than in the economically 
developed world. This may be due to a number of factors, including higher infection 
rates of organisms such as salmonella due to suboptimal hygiene. Furthermore, there 
may be a higher prevalence of immunosuppression due to malnutrition and the HIV 
epidemic.  However, the high incidences of septicemia may partly reflect that 
admission is delayed because caretakers do not have sufficient funds to pay for 
transport, admission fees etcetera.  
Amore accurate way of describing the incidence of bacteremia/septicemia is by 
estimating minimal annual incidences (MAI) expressed as the number of occurrences 
of the condition in the total population per year. The calculation of MAI requires 
population-based studies in the sense that there is knowledge about the size of the 
population, which would come to the study site if falling sick. Thus, such studies may 
be easier to perform in rural areas or small towns where there are a limited number of 
health facilities that handle cases. In the rural area in Kilifi, Kenya, the minimal 
annual incidence of community-acquired bacteremia was estimated at 1.5% of infants 
under one year of age, 1.1% among children under two years, and 0.5% of children 
under five years [8]. In The Gambias, an incidence of community-acquired 
bacteremia of 1.1% and 1.0% was found in children aged 2-29 months who had 
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received or not received pneumococcal conjugate vaccine [180]. The study site for 
our study was a university teaching hospital in a major city with several million 
inhabitants and, apart from the study hospital, there are several four public district 
hospitals, several private hospitals and a great number of health centers and 
pharmacies, all of which may treat children with systemic bacterial infections. Thus, 
since we do not have sufficient information on size of the population that actually 
uses MUCHS as a primary hospital we are not able to calculate any accurate estimate 
of minimal annual incidence of pediatric bacteremia from our study.  
6.7 Prevalence of organisms causing septicemia 
Bloodstream infections caused by Klebsiella spp. are much more common in 
developing countries, and particularly in hospital-acquired neonatal infections [91, 
181]. Klebsiella spp. were the most common cause of neonatal septicemia in our 
study (paper 2) as well, particularly in early-onset septicemia, and Klebsiella spp. and 
S. aureus were the most frequent agents causing hospital-acquired infections. It has 
been estimated that 70% of infections caused by Klebsiella spp. in developing 
countries will not be covered by the widely used empirical treatment with ampicillin 
and gentamicin due to inherent ampicillin resistance and emerging acquired 
resistance to gentamicin [91]. Again, our study (paper 2) supports these findings, as 
half of the isolates of Klebsiella spp. were resistant to gentamicin.  
Salmonella is one of the major causes of bacteremia in African children and has been 
linked to various risk factors, including malnutrition, recent malaria, HIV co-
infection[169, 175, 182]. In line with other studies, our study showed that salmonella 
was the most common pathogen causing septicemia in children older 1month, and, 
along with E. coli, the most common cause of community-acquired septicemia.  
Pneumococci are a major cause of invasive disease and child death [183, 184], but 
were not detected in our study of bloodstream infections (paper 2). Possible reasons 
for this may be antimicrobial therapy prior to blood culture and a selection bias, as 
people with pneumococcal disease may already have been treated and/or cured with 
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penicillin in other health facilities. Human blood is used in agar-production in the lab, 
and it has been speculated that this may be suboptimal, since there may be remnants 
of antimicrobials in the blood that may inhibit bacterial growth. 
6.8 Septicemia versus malaria 
The incidence of septicemia in the study (paper 2) was high (13.9%). While malaria 
was more frequent (21.6%), septicemia was involved in more deaths. In a study from 
Rwanda in the 1980s [129] the case-fatality rate of malaria was similar to that of 
bloodstream infection. However, in our study, bloodstream infection was associated 
with a much higher case-fatality rate than malaria. This is in line with the study from 
Kenya [8], where deaths from bloodstream infection also outnumbered malaria 
deaths. A reason for the trend of higher case-fatality rate in bloodstream infections 
than in malaria may be that antimicrobial resistance is seriously undermining the 
treatment strategies for bacterial bloodstream infections, while malaria still can be 
effectively treated with quinine. In view of this, it is an unfortunate and pressing 
dilemma that bloodstream infection and malaria are difficult to distinguish based on 
clinical presentation [9, 10, 185-187]. 
6.9 Septicemia and HIV infection 
The HIV-prevalence (16.8%) in the study-population (paper 2) was higher than 
national average (7%), which may be explained by the selection of study population 
and refusal by some relatives to test their child. Contrary to others [40-42], we did not 
find any significant association between HIV co-infection and resistance to drugs 
such as co-trimoxazole, which is used prophylaxis against Pneumocystis jirovecii 
pneumonia. However, HIV-positive children did receive inappropriate antibacterial 
therapy more frequently than HIV-negative.  
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6.10 Clinical outcome 
It has been shown that prompt antimicrobial treatment is important for the survival of 
patients with bacterial bloodstream infection [188]. An adverse impact of 
antimicrobial resistance on survival has been shown for certain problematic 
organisms such as MRSA [64, 65] and VRE [58, 59]. However, for other resistant 
microbes, such as ESBL-producers, there is a relative lack of scientific proof of an 
impact on mortality [49, 70]. Our bloodstream infection study (paper 2 & 3) confirms 
that inappropriate treatment of bloodstream infections due to antimicrobial resistance 
increases the risk of fatal outcome, and this association seems to be independent of 
underlying diseases as shown by logistic regression. The study also shows that both 
HIV-infection and malnutrition adversely affected the outcome of the patients as 
well. 
Although the numbers are small, the case-fatality rate of meningitis caused by S. 
Enteritidis in Northern Tanzania was 100% (5/5). The strain responsible for the 
outbreak was resistant to two of the first-line drugs, ampicillin and chloramphenicol, 
but sensitive to gentamicin, which is in line with reports of multi-drug-resistant S. 
Enteritidis in the region [189]. We speculate that the high case-fatality rate in these 
patients was partly due to antimicrobial resistance. The children were given 
ampicillin + gentamicin. Since the strain was resistant to ampicillin, the clinical 
outcome demonstrates that effective monotherapy with gentamicin probably is 
suboptimal as treatment for S. Enteritidis meningitis. 
In the bacteriuria study in Northern Tanzania (paper 5), growth of E. coli from a 
urinary specimen was associated with a significantly increased relative risk for 
negative outcome of the pregnancy. This finding is in line with previous studies by 
Kass and others [17-19], but unexpected in the sense that all women with positive dip 
slides received nitrofurantoin treatment and, thus, should have been cured from their 
bacteriuria. A plausible explanation for this may be that compliance with treatment is 
low, and particularly so in asymptomatic persons.  
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6.11 Strengths and limitations 
Selection bias is a serious and easily overlooked potential source of error in studies 
assessing antimicrobial. When studies are performed at major hospitals in urban 
centers such as MUCHS, Dar es Salaam, there is a possibility that many patients 
receive antimicrobial therapy at primary or secondary health services prior to 
presenting at the tertiary hospital. Persons with infections with susceptible bacteria 
may well be cured at the primary health facility and never come to the major hospital, 
while people with infections with resistant bacteria will not be cured at the periphery, 
and may eventually end up coming to the major hospital. We have quantified the 
problem with antimicrobial treatment prior to blood-culture (paper 2), and speculate 
on its implication, e.g. for reduced detection of fastidious organisms. We have tried to 
address problem with the selection bias by also performing susceptibility studies in an 
unselected population in a rural part of Tanzania, and this exercise confirms that there 
are differences in antimicrobial susceptibility patterns between urban and rural areas. 
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7. Conclusions 
Data from this thesis shows that: 
- Computerized surveillance of antimicrobial resistance can be implemented at a 
tertiary hospital in Tanzania at low cost.  
- The resistance surveillance system can 1) provide useful information on 
antimicrobial resistance patterns, 2) function as a quality assurance tool, 3) 
increase awareness of the resistance issues, and 4) pinpoint particular 
resistance-problems which needs to be targeted by dedicated research. 
- Bacterial bloodstream infections are a frequent cause of morbidity in 
hospitalized children in Dar es Salaam and associated with higher case-fatality 
rates than malaria. 
- There are high rates of antimicrobial resistance, particularly in Gram-negative 
bacteria causing bloodstream infections. 
- Bacteria that produce ESBL (including SHV-12, TEM-63 and CTX-M-15) 
have been described for the first time in Tanzania. 
- ESBL-type and other resistance mechanisms towards given antimicrobial 
therapy are significant risk factors for death from bloodstream infections.  
- Meningitis caused by ampicillin-resistant S. Enteritidis was uniformly fatal in 
neonates receiving combination therapy with ampicillin and gentamicin, but 
the problem diminished upon reinforcement of hygiene. 
- Growth of E. coli in urine culture from pregnant women was correlated with 
adverse outcome of pregnancy. 
- The rates of resistance towards antimicrobials vary within a country, with 
lower rates in remote, rural areas than in populated urban centers. 
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8. Recommendations 
Hospitals with bacteriology laboratories, such as MUCHS, should implement 
computerized systems for surveillance of antimicrobial resistance. 
As far as possible, standardized methods should be used for susceptibility testing. 
Currently there is lack of standardization at international level, and efforts to 
harmonize resistance surveillance efforts across borders should continue [190, 191].  
All measures must be taken to limit the further spread of antimicrobial resistance 
traits, particularly the ESBL-type resistance. This may include: 
- Restrictions on antimicrobial use and prescriptions. 
- Reemphasizing rational antimicrobial use, including the use of narrow-
spectrum rather than broad-spectrum antimicrobials, when appropriate. 
- Reinforcement of hygiene, particularly in hospitals. 
Currently, multidrug-resistant, ESBL-producing Gram-negative bacteria, which cause 
bloodstream infections, are susceptible to few or none of the available antimicrobials 
in Tanzania. Despite previous concern regarding adverse effects of fluoroquinolones 
in children, drugs such as ciprofloxacin can be resorted to for treatment of life-
threatening infections [192, 193]. 
The described nosocomial outbreak of nontyphoid salmonella-meningitis underlines 
the importance of stringent hygiene, particularly in neonatal wards. 
The bacteriuria study supports the notion that asymptomatic bacteriuria and urinary 
tract infection in pregnant women should be treated.  
Differences in antimicrobial resistance between rural and urban areas should be taken 
into account when formulating guidelines for use of antimicrobial agents. 
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